Practical management of patients with chronic myeloid leukemia receiving imatinib

Journal of Clinical Oncology

Volumn 21, Issue 8, 2003, Pages 1637-1647

  Deininger, Michael W N ^a   O'Brien, Stephen G ^a   Ford, John M ^a   Druker, Brian J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMATINIB; ANTINEOPLASTIC AGENT; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; ENZYME INHIBITOR; HEMOPOIETIC GROWTH FACTOR; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ARTHRALGIA; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG USE; EDEMA; FATIGUE; HEADACHE; HUMAN; MEDICAL INFORMATION; MUSCLE CRAMP; MYALGIA; NAUSEA; OPTIMAL DRUG DOSE; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; TREATMENT RESPONSE; BONE MARROW; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG ERUPTION; DRUG INTERACTION; LIVER; PATHOLOGY; VOMITING;

ANTINEOPLASTIC AGENTS; ARTHRALGIA; BONE MARROW; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; DRUG INTERACTIONS; EDEMA; ENZYME INHIBITORS; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LIVER; MUSCLE CRAMP; NAUSEA; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; VOMITING;

EID: 0038518619     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.143     Document Type: Review

References (35)

1. Buchdunger E, Zimmermann J, Mett H, et al: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A 92:2558-2562, 1995
2. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nature Med 2:561-566, 1996
3. Heinrich MC, Griffith DJ, Druker BJ, et al: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-932, 2000
4. Okuda K, Weisberg E, Gilliland DG, et al: ARG tyrosine kinase activity is inhibited by STI571. Blood 97:2440-2448, 2001
5. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002
6. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
7. Druker BJ, Talpaz M, Resta D, et al: Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
8. Sawyers CL, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a phase II study. Blood 99:3530-3539, 2002
9. Talpaz M, Silver RT, Druker BJ, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928-1937, 2002
10. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003
11. Braziel RM, Launder TM, Druker BJ, et ai: Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 100:435-441, 2002
12. Deininger MW, Goldman JM, Lydon N, et ai: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691-3698, 1997
13. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001
14. O'Dwyer ME, Mauro MJ, Kurilik G, et al: The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100:1628-1633, 2002
15. Cortes JE, Talpaz M, O'Brien S, et al: High rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia in early chronic phase treated with imatinib at 400 mg or 800 mg daily. Blood 100:95a, 2002 (abstr 350)
16. Peng B, Hayes M, Racine-Poon A, et al: Clinical investigation of the pharmacokinetic/pharmacodynamic relationship for Glivec (STI571): A novel inhibitor of signal transduction. Proc Am Soc Clin Oncol 20:71a, 2001 (abstr 280)
17. Mauro MJ, O'Dwyer ME, Kurilik G, et al: Risk factors for myelosuppression in chronic phase CML patients treated with imatinib mesylate (STI571). Blood 98:139a, 2001 (abstr 585)
18. Marin D, Bua M, Marktel S, et al: The combination of cytogenetic response after 6 months treatment with STI571 and the presence of cytopenias in patients with CML in chronic phase resistant to or intolerant of interferon-alfa defines four different prognostic groups. Blood 98:846a, 2001 (abstr 3514)
19. Petzer AL, Eaves CJ, Lansdorp PM, et al: Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 88:2162-2171, 1996
20. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
21. Mauro MJ, Kurilik G, Balleisen S, et al: Myeloid growth factors for neutropenia during imatinib mesylate (STI571) therapy for CML: Preliminary evidence of safety and efficacy. Blood 98:139a, 2001 (abstr 584)
22. Reckmann AH, Fischer T, Peng B, et al: Effect of food on STI571 (Glivec) pharmacokinetics and bioavailability. Proc Am Soc Clin Oncol 20:307, 2001 (abstr 1223)
23. Esmaeli B, Prieto VG, Butler CE, et ai: Severe periorbital edema secondary to STI571 (Gleevec). Cancer 95:881-887, 2002
24. Ebnoether M, Stentoft J, Ford J, et al: Cerebral oedema as a possible complication of treatment with imatinib. Lancet 359:1751-1752, 2002
25. Lindahl P, Johansson BR, Leveen P, et al: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:242-245, 1997
26. Koleske AJ, Gifford AM, Scott ML, et al: Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron 21:1259-1272, 1998
27. Hsiao LT, Chung HM, Lin JT, et al: Stevens-Johnson syndrome after treatment with STI571: A case report. Br J Haematol 117:620-622, 2002
28. Lammie A, Drobnjak M, Gerald W, et al: Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem 42:1417-1425, 1994
29. Etienne G, Cony-Makhoul P, Mahon FX: Imatinib mesylate and gray hair. N Engl J Med 347:446, 2002
30. O'Brien SG, Peng B, Dutreix C, et al: A pharmacokinetic interaction of Glivec® and simvastatin, a cytochrome 3A4 substrate, in patients with chronic myeloid leukemia. Blood 98:141a, 2001 (abstr 593)
31. Ottmann OG, Druker BJ, Sawyers CL, et al: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965-1971, 2002
32. Goldman JM, Druker BJ: Chronic myeloid leukemia: Current treatment options. Blood 98:2039-2042, 2001
33. O'Dwyer ME, Mauro MJ, Blasdel C, et al: Lack of cytogenetic response is an adverse prognostic factor for relapse of chronic phase CML patients treated with imatinib mesylate (STI571). Blood 98:137a, 2001 (abstr 579)
34. Hughes T, Kaeda J, Branford S, et al: Molecular responses to imatinib (STI571) or interferon + Ara-C as initial therapy for CML: Results in the IRIS study. Blood 100:93a, 2002 (abstr 345)
35. Lacy CF, Armstrong LL, Goldman MP, et ai: Drug Information Handbook (ed 9). Hudson, OH, Lexi-Comp Inc, 2001, pp 1376-1384